BUZZ-Galmed Pharma rises after positive results of liver drug formulation study

Reuters11-18

** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O rise 7% to $1.13

** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study

** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose

** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases

** Up to last close, stock down 67.1% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584568239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584568239","market":"fut","top_or_hot":-1,"title":"BUZZ-Galmed Pharma rises after positive results of liver drug formulation study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Galmed Pharma rises after positive results of liver drug formulation study</title></head><body><p>** Shares of Israel-based drug developer Galmed Pharmaceuticals <span>GLMD.O</span> rise 7% to $1.13 </p><p>** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study </p><p>** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose</p><p>** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases</p><p>** Up to last close, stock down 67.1% YTD </p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Galmed Pharma rises after positive results of liver drug formulation study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Galmed Pharma rises after positive results of liver drug formulation study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Galmed Pharma rises after positive results of liver drug formulation study</title></head><body><p>** Shares of Israel-based drug developer Galmed Pharmaceuticals <span>GLMD.O</span> rise 7% to $1.13 </p><p>** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study </p><p>** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose</p><p>** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases</p><p>** Up to last close, stock down 67.1% YTD </p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nL4N3WU104:1","article_id":"2584568239","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584568239","pubTimestamp":1763477378,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Galmed Pharma rises after positive results of liver drug formulation study** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O rise 7% to $1.13 ** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study ** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases** Up to last close, stock down 67.1% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLMD":"Galmed Pharmaceuticals Ltd."},"translate_title":"肝脏药物配方研究取得积极结果后，Galmed Pharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLMD":0.9},"content_text":"BUZZ-Galmed Pharma rises after positive results of liver drug formulation study** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O rise 7% to $1.13 ** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study ** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases** Up to last close, stock down 67.1% YTD  (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584568239","isCrawlerRequest":true}